- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:00 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 59 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| Mo | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 128 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 23.09. | Proteomedix vereinbart Lizenzabkommen mit Immunovia | 1 | punkt4.info | ||
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 22.09. | Onconetix-Tochter lizenziert Biomarker-Technologie an Immunovia | 1 | Investing.com Deutsch | ||
| 22.09. | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 385 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09. | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 115 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09. | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 84 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09. | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 134 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08. | Immunovia Q2 2025 slides: PancreaSure launch plan unveiled amid stock decline | 3 | Investing.com | ||
| 28.08. | Immunovia-Aktie bricht nach Q2-Zahlen ein - trotz neuem Krebstest | 3 | Investing.com Deutsch | ||
| 28.08. | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 88 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08. | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 293 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08. | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 117 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 217 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 225 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 202 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 189 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 245 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 312 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 384 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 48,240 | -0,12 % | HeraMED beschleunigt seinen KI-Fahrplan - Die nächste Phase der Frauengesundheit beginnt jetzt | ||
| BECTON DICKINSON | 157,25 | -1,35 % | RBC starts Becton Dickinson at Sector Perform, sees limited upside until 2027 | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,201 | +0,67 % | RYMAN HEALTHCARE LIMITED: Ryman Healthcare lists on the ASX | ||
| SOLENO THERAPEUTICS | 56,45 | -2,00 % | H.C. Wainwright reiterates Buy rating on Soleno Therapeutics stock at $110 | ||
| NIAGEN BIOSCIENCE | 8,300 | +4,40 % | Niagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London Conference | Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 11,300 | 0,00 % | Dividendenbekanntmachungen (29.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1777 EUR ACOM CO LTD JP3108600002 10 JPY 0,0572 EUR ADVANTEST CORPORATION JP3122400009 19... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 1,480 | 0,00 % | MICROPORT (00853): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, 22 OCTOBER 2025 | ||
| EXTENDICARE | 9,050 | -1,63 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
| VERADIGM | 4,000 | +21,21 % | Veradigm: Umsatzrückgang im zweiten Quartal und Abschluss des Wandelanleihen-Rückkaufs | ||
| NATIONAL HEALTHCARE CORPORATION | 101,00 | -0,98 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,760 | -3,25 % | TIGERMED (03347): ARTICLES OF ASSOCIATION | ||
| UNIPHAR | 3,890 | +0,52 % | Dividendenbekanntmachungen (11.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,13 USD 0,1111 EUR ACTIA GROUP SA FR0000076655 - 0,12 EUR ADT INC US00090Q1031 0... ► Artikel lesen | |
| AESTHETIC MEDICAL INTERNATIONAL | 0,152 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 6-K, Report of foreign issuer | ||
| SIEMENS HEALTHINEERS | 46,820 | +1,74 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Siemens Healthineers auf "Buy" mit einem Kursziel von 60 Euro belassen. Die am 5. November anstehenden Schlussquartalszahlen dürften es dem... ► Artikel lesen |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,025 Euro und damit -0,79 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.